From March 12 to 14, 2026, Murcia hosted the XIX National Congress of Private Psychiatry, a professional meeting focused on current challenges in mental health, clinical practice, and innovation in healthcare. In this edition, Dr. Josep Maria Fábregas Pedrell, founder and medical director of Clínicas CITA, participated as a speaker in two round tables of special relevance for the present and future of private psychiatric care.
Dr. Fábregas’s participation reinforces a fundamental line of work: bringing real clinical experience to professional debates on private psychiatry and clinical innovation, especially in complex areas such as addictions, therapeutic hospitalization, and the medical use of substances that have long been surrounded by stigma.
Private psychiatry and clinical innovation: a necessary debate
Private psychiatry now occupies a relevant place within the healthcare system. Not only because of its ability to offer personalized treatments, but also for its role in incorporating new therapeutic models, intensive programs, and multidisciplinary approaches.
CONTACTAR CON CLÍNICAS CITA AHORA
In this context, talking about private psychiatry and clinical innovation does not only mean introducing new technologies or emerging treatments. It also implies reviewing how patients are supported, how teams are coordinated, how work is done with families, and how programs capable of responding to increasingly complex clinical situations are designed.
A view from clinical experience
The value of Dr. Fábregas’s participation lies precisely in his clinical approach. His career is closely linked to addiction treatment and residential care, two areas where innovation must always be accompanied by prudence, evidence, and medical judgment.
In mental health, innovating is not replacing experience with novelty. Innovating is improving what already works, reviewing what can be done better, and opening spaces for collaboration among professionals, centers, and disciplines.
“Drug or medicine: the clinical perspective”
One of Dr. Fábregas’s presentations was titled “Drug or medicine: the clinical perspective,” within the round table “Psychedelics: from stigma to prescription.”
This topic connects with one of the most current debates in psychiatry: the possible therapeutic use of substances that, for decades, have been considered only drugs of abuse. Scientific research on psychedelics and other compounds is advancing, but their clinical application requires caution, regulation, professional training, and highly controlled medical contexts.
From stigma to medical criteria
The shift “from stigma to prescription” cannot be understood as limitless normalization. On the contrary, it forces us to differentiate between recreational use, problematic consumption, clinical research, and possible therapeutic indication.
From clinical practice, the question is not only whether a substance may have therapeutic potential. The truly important question is: in which patients, under what conditions, with what supervision, with what objectives, and with what risks?
This is where experience in addictions is essential. A medication can be useful in a medical context and dangerous outside of it. A substance may have promising effects in research, but also risks if used without indication, without follow-up, or in vulnerable people.
Private hospitalization: innovation and collaboration
Dr. Fábregas’s second participation took place in the round table “Hospitalization treatments in the private sector: innovation and collaboration.”
Hospitalization in mental health and addictions remains an essential resource for certain patients. Especially when there is a loss of control, a risk situation, clinical decompensation, or a need for temporary separation from the usual environment.
Intensive treatments and therapeutic environments
In the private sector, hospitalization allows for the design of intensive intervention programs that combine medical care, psychotherapy, therapeutic support, structured habits, and individualized follow-up.
This type of treatment should not be understood solely as an admission. It is a clinical process that requires evaluation, concrete objectives, a multidisciplinary team, and continuity of care. Innovation, in this case, involves improving coordination among professionals, adapting treatments to each patient’s profile, and creating therapeutic environments where the person can initiate real change.
Collaborating to treat better
Collaboration among centers, doctors, psychiatrists, psychologists, therapists, families, and other healthcare professionals is key to improving outcomes. In mental health, no resource works in isolation. Recovery often requires a network.
That is why meeting spaces like the XIX National Congress of Private Psychiatry are important: they allow us to share experience, compare models, and build a more solid clinical practice.
Commitment to rigorous and humane psychiatry
Dr. Fábregas’s presence at this congress reflects Clínicas CITA’s commitment to a way of working based on clinical experience, professional updating, and human care. At a time when mental health is taking up more and more space in public conversation, it is essential that professional debates maintain rigor, especially when talking about innovative treatments, hospitalization, and addictions.
Private psychiatry and clinical innovation must advance together, but always with responsibility. Innovation only makes sense if it improves the patient’s life, reduces risks, and is integrated into an ethical, safe, and personalized treatment.
From Clínicas CITA, we celebrate Dr. Josep Maria Fábregas’s participation in this professional meeting and reaffirm our commitment to specialized care in addictions and mental health, based on experience, collaboration, and continuous improvement.
